Clinical Trials Browser

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Carcinoma, Intraductal, Noninfiltrating

Breast Carcinoma In Situ

Breast Neoplasms

Triple Negative Breast Neoplasms

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Female

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Male

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Breast Neoplasms

ERα+ Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Endometrial Hyperplasia, Endometrial Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Glioblastoma

Breast Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Infertility

Breast Neoplasms, Carcinoma, Lobular

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Risk Reduction Behavior

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

ER+ Breast Cancer

Breast Neoplasms

Breast Neoplasms

Neuroendocrine Tumors

Clinical Trials

MNEMOSYNE

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

LoTam

DEBRA

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

POWER II

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

POETIC-A

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

ETHAN - ET for Male BC

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

LDTam

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

BabyTears

ADEPT

AURA

Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen

EUROPA

TOLERANT

METALLICA

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

CAMERAN

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

TICTOC

TALES

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

PHERGain

KARISMA2

ASPIRE

Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer

Karisma-1

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

TRAK-ER

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

HORMONET